Newsmeme!
Discover News you didn't know existed

• home
• news
• tagging
• how it works
• about
• data

Blepharitis

News

Lux Biosciences Announces European Medicines Agency Acceptance of Its Pediatric Investigation Plan for LUVENIQ

Published November 26, 2008, 5:01 am, Business Wire via Yahoo! Finance

JERSEY CITY, N.J.----Lux Biosciences today announced that the Pediatric Committee of the European Medicines Agency has issued a positive opinion on Lux’s Pediatric Investigation Plan for LUVENIQ™ , the company’s potential first-in-class product in Phase 3 development for sight-threatening non-infectious uveitis.

Full Story

Tags

No tags found at this time. Be the first to tag this news item, learn more.

Imagery

Related Blepharitis Stories

From Various News Sources

Isotechnika's Partner Receives European Medicines Agency Acceptance of ... - Phramalive.com
EDMONTON, Nov. 26 /CNW/ - Isotechnika Inc. announced today that its partner, Lux Biosciences Inc., received a positive opinion from the Pediatric Committee of the European Medicines Agency (EMEA) regarding their Pediatric Investigation Plan (PIP) for ...

Lux Biosciences Announces European Medicines Agency Acceptance of Its ... - Phramalive.com
JERSEY CITY, N.J.--(BUSINESS WIRE)--Nov 26, 2008 - Lux Biosciences today announced that the Pediatric Committee of the European Medicines Agency (EMEA) has issued a positive opinion on Lux's Pediatric Investigation Plan (PIP) for LUVENIQ? (oral ...

Lux Biosciences Announces European Medicines Agency Acceptance of Its ... - Businesswire.com
JERSEY CITY, N.J.--( BUSINESS WIRE )--Lux Biosciences today announced that the Pediatric Committee of the European Medicines Agency (EMEA) has issued a positive opinion on Lux?s Pediatric Investigation Plan (PIP) for LUVENIQ? (oral formulation of ...

Lux Biosciences Announces European Medicines Agency Acceptance of Its ... - PR Inside
www.luxbio.com - Lux Biosciences today announced that the Pediatric Committee of the European Medicines Agency (EMEA) has issued a positive opinion on Lux"s Pediatric Investigation Plan (PIP) for LUVENIQ" (oral formulation of voclosporin), the ...

Related Social Bookmarks

None found at this time.